专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06319928B1 Purine derivatives having phosphodiesterase IV inhibition activity 失效
标题翻译：具有磷酸二酯酶IV抑制活性的嘌呤衍生物
公开(公告)号：US06319928B1
公开(公告)日：2001-11-20
申请号：US09418331
申请日：1999-10-14
申请人： Mark Chasin , David J. Cavalla , Peter Hofer , Peter Wintergerst , Andre Gehrig
发明人： Mark Chasin , David J. Cavalla , Peter Hofer , Peter Wintergerst , Andre Gehrig
IPC分类号： C07D47318
CPC分类号： C07D473/20 , C07D473/18 , C07D473/24 , C07D473/34
摘要： A compound of the formula: wherein R2 is O or S; R3, R6a and R8 are the same or different and each represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC═NOH, HC═NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl; R6b represents a H or R6a, or together R6b, N, and R6a make a 3 to 8 member ring containing at least one carbon, from one to three nitrogen atoms, from zero to two oxygen atoms, from zero to two sulfur atoms, said ring optionally substituted with alkoxy, CO2H, CONH2, ═NOH, ═NOCONH2, ═O; and where aryl is phenyl or naphthyl, the heterocyclyl is a 5, 6 or 7 membered ring including from one to three nitrogen atoms, and from zero to two oxygen atoms, from zero to two sulfur atoms, and can be substituted as in aryl on the carbons or nitrogens of that ring; or a pharmaceutically acceptable salt thereof, provided that when R3 is propyl, R8 is not cyclopentyl, noradamantyl, or dicyclopropylmethyl.
摘要翻译：下式的化合物：其中R 2是O或S; R 3，R 6a和R 8相同或不同，并且各自表示未支链或未支化或被OH，烷氧基，CO 2 H，= NOH = NOCONH2或= O; 未取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代的C 3-8环烷基; C4-8环烷基烷基，其中环烷基部分未被取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代; 未取代或被Cl，NH 2，烷基氨基，二烷基氨基，酰氨基，C 1 -C 8烷基酰氨基，C 1 -C 3二烷基氨基，OH，烷氧基，HC = NOH，HC = NOCONH 2，C 1 -C 3烷基，苯基或苄基取代的芳基; 芳烷基（C1-4）; 杂环基杂环基烷基（C1-C4）; 和杂芳基; R6b表示H或R6a，或R6b，N和R6a一起形成含有至少一个碳，1-3个氮原子，0至2个氧原子，0至2个硫原子的3至8元环所述环任选被烷氧基取代，CO 2 H，CONH 2，= NOH，= NOCONH 2，= O; 并且其中芳基为苯基或萘基，杂环基为5,6或7元环，包括1至3个氮原子，0至2个氧原子，0至2个硫原子，并且可以如该环的碳或氮; 或其药学上可接受的盐，条件是当R 3为丙基时，R 8不是环戊基，去甲金刚烷基或二环丙基甲基。

2. 发明授权

US06228859B1 Purine derivatives having phosphodiesterase IV inhibition activity 失效
标题翻译：具有磷酸二酯酶IV抑制活性的嘌呤衍生物
公开(公告)号：US06228859B1
公开(公告)日：2001-05-08
申请号：US09210556
申请日：1998-12-11
申请人： David J. Cavalla , Mark Chasin , Peter Hofer , Andre Gehrig , Peter Wintergerst
发明人： David J. Cavalla , Mark Chasin , Peter Hofer , Andre Gehrig , Peter Wintergerst
IPC分类号： C07D47334
CPC分类号： C07D473/30 , C07D473/34
摘要： Disclosed are compounds of the formula (I): wherein R3 is selected from the group consisting of C1-10 alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy substituent is optionally substituted in one position with hydroxy; R8 is selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy is optionally substituted in one position with hydroxy; R6a and R6b are independently selected from the group consisting of hydrogen, C1-10 alkyl, C1-10 alkenyl, C3-10 cycloalkyl, C4-10 cycloalkylalkyl, or C3-10 cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; and pharmaceutically acceptable salts thereof.
摘要翻译：公开了式（I）的化合物：其中R 3选自C 1-10烷基，C 1-10烯基，C 3-10环烷基，C 4-10环烷基烷基或C 3-10环烯基，其中所述烷基，烯基，环烷基环烷基烷基或环烯基任选在一个位置被羟基取代; 或苄基，其中所述苄基在一个或两个位置任选被卤素，烷氧基，环烷氧基或多环烷基取代，并且其中所述烷氧基或环烷氧基取代基的所述烷基部分任选在一个位置被羟基取代; R 8选自的氢，C 1-10烷基，C 1-10烯基，C 3-10环烷基，C 4-10环烷基烷基或C 3-10环烯基，其中所述烷基，烯基，环烷基，环烷基烷基或环烯基任选在一个位置被羟基取代; 或苄基，其中所述苄基在一个或两个位置任选被卤素，烷氧基，环烷氧基或多环烷基取代，并且其中所述烷氧基或环烷氧基的所述烷基部分任选在一个位置被羟基取代; R 6a和R 6b独立地选自由氢，C 1-10烷基，C 1-10烯基，C 3-10环烷基，C 4-10环烷基烷基或C 3-10环烯基组成的基团，其中所述烷基，链烯基，环烷基，环烷基烷基或环烯基任选在一个位置被羟基取代 ;及其药学上可接受的盐。

3. 发明授权

US06413975B1 Purine derivatives having phosphodiesterase iv inhibition activity 失效
标题翻译：具有磷酸二酯酶iv抑制活性的嘌呤衍生物
公开(公告)号：US06413975B1
公开(公告)日：2002-07-02
申请号：US09539571
申请日：2000-03-31
申请人： Mark Chasin , David J. Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst
发明人： Mark Chasin , David J. Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst
IPC分类号： C07D47334
CPC分类号： C07D473/18 , C07D473/20 , C07D473/24 , C07D473/34
摘要： Disclosed are compounds of the formula: wherein R3, R6a, R6b and R8 are substituted as disclosed herein. The compounds are effective in effecting PDE IV inhibition in patients in need thereof.
摘要翻译：公开了下式的化合物：其中R 3，R 6a，R 6b和R 8如本文所公开的被取代。该化合物在有需要的患者中有效地实现PDE IV抑制。

4. 发明授权

US06294541B1 Purine derivatives having phosphodiesterase IV inhibition activity 失效
标题翻译：具有磷酸二酯酶IV抑制活性的嘌呤衍生物
公开(公告)号：US06294541B1
公开(公告)日：2001-09-25
申请号：US09418330
申请日：1999-10-14
申请人： David J. Cavalla , Mark Chasin , Peter Hofer , Andre Gehrig , Peter Wintergerst
发明人： David J. Cavalla , Mark Chasin , Peter Hofer , Andre Gehrig , Peter Wintergerst
IPC分类号： C07D27320
CPC分类号： C07D473/24 , C07D473/18 , C07D473/20 , C07D473/30 , C07D473/34
摘要： A compound of the formula: wherein R3 represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC═NOH, HC═NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl; R8 represents H or a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C3-8 cycloalkyl which is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; C4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted with OH, alkoxy, CO2H, ═NOH, ═NOCONH2, or ═O; aryl which is unsubstituted or substituted with Cl, NH2, alkylamino, dialkylamino, amido, C1-C8 alkylamido, C1-C3 dialkylamido, OH, alkoxy, HC═NOH, HC═NOCONH2, C1-C3 alkyl, phenyl or benzyl; aralkyl (C1-4); heterocyclyl; heterocyclylalkyl (C1-C4); and heteroaryl.
摘要翻译：下式的化合物：其中R 3表示未支链或未支化或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代的C 1-8烷基; 未取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代的C 3-8环烷基; C4-8环烷基烷基，其中环烷基部分未被取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代; 未取代或被Cl，NH 2，烷基氨基，二烷基氨基，酰氨基，C 1 -C 8烷基酰氨基，C 1 -C 3二烷基氨基，OH，烷氧基，HC = NOH，HC = NOCONH 2，C 1 -C 3烷基，苯基或苄基取代的芳基; 芳烷基（C1-4）; 杂环基杂环基烷基（C1-C4）; R 8表示H或未分支或未被取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代的C 1-8烷基; 未取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代的C 3-8环烷基; C4-8环烷基烷基，其中环烷基部分未被取代或被OH，烷氧基，CO 2 H，= NOH，= NOCONH 2或= O取代; 未取代或被Cl，NH 2，烷基氨基，二烷基氨基，酰氨基，C 1 -C 8烷基酰氨基，C 1 -C 3二烷基氨基，OH，烷氧基，HC = NOH，HC = NOCONH 2，C 1 -C 3烷基，苯基或苄基取代的芳基; 芳烷基（C1-4）; 杂环基杂环基烷基（C1-C4）; 和杂芳基。

5. 发明授权

US6075016A 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity 失效
标题翻译：具有增强的磷酸二酯酶IV抑制活性的6,5-稠合芳环体系
公开(公告)号：US6075016A
公开(公告)日：2000-06-13
申请号：US833893
申请日：1997-04-10
申请人： Mark Chasin , David Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst
发明人： Mark Chasin , David Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst
IPC分类号： C07D263/56 , C07D413/06 , C07D417/06 , A61K31/40 , A61K31/435 , C07D471/04 , C07D498/04
CPC分类号： C07D263/56 , C07D413/06 , C07D417/06
摘要： Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. The present invention includes compounds of Formula I: ##STR1##
摘要翻译：公开了作为有效的PDE IV抑制剂的新型化合物。与茶碱或咯利普兰相比，该化合物具有改善的PDE IV抑制，关于例如PDE V抑制具有改善的选择性。本发明包括式I的化合物：

6. 发明授权

US06365606B1 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity 失效
标题翻译：具有增强的磷酸二酯酶IV抑制活性的6,5-稠合芳环体系
公开(公告)号：US06365606B1
公开(公告)日：2002-04-02
申请号：US09506624
申请日：2000-02-18
申请人： David Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst , Mark Chasin
发明人： David Cavalla , Peter Hofer , Andre Gehrig , Peter Wintergerst , Mark Chasin
IPC分类号： A61K314402
CPC分类号： C07D263/56 , C07D413/06 , C07D417/06
摘要： Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. The present invention includes compounds of Formula I: wherein the substituents are as disclosed herein.
摘要翻译：公开了作为有效的PDE IV抑制剂的新型化合物。与茶碱或咯利普兰相比，该化合物具有改善的PDE IV抑制作用，具有关于例如PDE V抑制的改善的选择性。本发明包括式I的化合物：其中取代基如本文所公开。

7. 发明授权

US6037470A Purine compounds having PDE IV inhibitory activity and methods of synthesis 有权
标题翻译：具有PDE IV抑制活性的嘌呤化合物和合成方法
公开(公告)号：US6037470A
公开(公告)日：2000-03-14
申请号：US209658
申请日：1998-12-10
申请人： David J. Cavalla , Mark Chasin , Peter Hofer
发明人： David J. Cavalla , Mark Chasin , Peter Hofer
IPC分类号： A61K31/52 , A61K31/53 , A61P11/00 , A61P11/06 , A61P25/24 , A61P25/28 , A61P27/16 , A61P29/00 , A61P29/02 , A61P31/18 , A61P37/04 , A61P37/08 , A61P43/00 , C07D471/04 , C07D473/30 , C07D473/34 , C07D487/04 , C07D239/56 , C07D473/22
CPC分类号： C07D473/30 , C07D473/34
摘要： The present invention comprises a method of synthesizing compounds of formula (I): wherein Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.8 are as described herein; comprising the steps of.(a) reacting a compound of the formula (II) ##STR1## with an effective amount of ethyl cyanoacetate to form a compound of the formula (III) ##STR2## (b) subjecting said compound (III) to successive steps of nitrosating with a nitrosating agent to form a nitro group [amination], reduction of the nitro group to an amine group with a reducing agent, and [amidation] acylation of the amine group to an amide group with an acylating agent, to form compound (IV) ##STR3## (c) reacting said compound (IV) with an effective amount of a base to form compound (V) ##STR4## (d) reacting said compound (V) with an effective amount of a desulfurization compound to form compound (VI) ##STR5## and (e) subjecting said oxo group of compound (VI) to the successive steps of halogenation with a halogenating agent and displacement with an amine of the formula NR.sup.1 R.sup.2, wherein R.sup.1 and R.sup.2 are as defined above, to form said compound of formula 1.
摘要翻译：本发明包括合成式（I）化合物的方法：其中Z，R1，R2，R3，R4和R8如本文所述; 包括以下步骤。（a）使式（II）的化合物与有效量的氰基乙酸乙酯反应以形成式（III）化合物（b）使所述化合物（III）与亚硝化剂连续进行亚硝化步骤以形成硝基[胺化]，用还原剂将硝基还原为胺基，用酰化剂将胺基酰胺化成酰胺基，形成化合物（Ⅳ）（c）使所述化合物（Ⅳ）与有效量的碱形成化合物（Ⅴ）（d）使所述化合物（Ⅴ）与有效量的脱硫化合物反应，形成化合物（Ⅵ）和（ⅱ）使所述化合物 VI）到用卤化剂卤化并用式NR 1 R 2的胺取代的连续步骤，其中R 1和R 2如上所定义，以形成所述式1化合物。

8. 发明授权

US06248746B1 3-(arylalkyl) xanthines 失效
标题翻译： 3-（芳烷基）黄嘌呤
公开(公告)号：US06248746B1
公开(公告)日：2001-06-19
申请号：US09227057
申请日：1999-01-07
申请人： Mark Chasin , David J. Cavalla , Peter Hofer
发明人： Mark Chasin , David J. Cavalla , Peter Hofer
IPC分类号： A61K3152
CPC分类号： A61K31/522 , C07D473/04 , C07D473/06
摘要： With the above and other objects in view, the present invention comprises compounds having the general formula (I): wherein: R1 is a C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, C3-8 cycloalkenyl or cycloalkynyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl or cycloalkynyl is optionally substituted with hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, halogen, oxo, carbamido, hydroxycarbamido, oximido, C1-5 alkyloximido, C3-5 cycloalkyloximido, C1-5 acyloximido or C3-5 cycloacyloximido; Q is methylene or ethylene; R3 is aryl or heteroaryl wherein said aryl or heteroaryl has one to three substituents selected from the group consisting of C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, cycloalkynyl, C3-5 alkylene, C3-5 cycloalkylene, haloC1-6 alkyl, haloC1-6 cycloalkyl, hydroxy, C1-5 alkoxy, C3-5 cycloalkoxy, C1-2 alkylenedioxy, C1-6 acyl, C3-6 cycloacyl, C1-6 acyloxy, C3-6 cycloacyloxy, halogen, nitro or cyano; R8 is C1-5 alkyl or C3-5 cycloalkyl, optionally substituted by hydroxy, C1-5 alkyloxy, C3-5 cycloalkyloxy, C1-5 acyloxy, C3-5 cycloacyloxy or halogen; and methods of using the compounds of formula I for treatment of patients who can benefit from a modification of PDE IV levels in their bodies.
摘要翻译：考虑到上述和其它目的，本发明包括具有通式（I）的化合物：其中：R 1是C 2-8烷基，C 2-8烯基，C 2-8炔基，C 3-8环烷基，C 3-8 环烯基或环炔基，其中所述烷基，烯基，炔基，环烷基，环烯基或环炔基任选被羟基，C 1-5烷氧基，C 3-5环烷氧基，卤素，氧代，氨基甲酰基，羟基氨基甲酰基，肟基，C 1-5烷基酰氧基， 5环烷酰肟基，C1-5酰氧亚氨基或C3-5环亚胺酰脒; Q是亚甲基或亚乙基; R 3是芳基或杂芳基，其中所述芳基或杂芳基具有一至三个选自C 1-6烷基，C 2-6烯基， C2-6炔基，C3-6环烷基，C3-6环烯基，环炔基，C3-5亚烷基，C3-5亚环烷基，卤代C 1-6烷基，卤代C 1-6环烷基，羟基，C 1-5烷氧基，C 3-5环烷氧基，C 1 -2亚烷基二氧基，C1-6酰基，C3-6环酰基，C1-6酰氧基，C3-6环酰氧基，卤素，硝基或氰基; R8是C1-5烷基或C3-5环任选地被羟基，C 1-5烷氧基，C 3-5烃环氧基，C 1-5酰氧基，C 3-5环芳氧基或卤素取代的烷基;以及使用式I化合物治疗可从PDE修饰中受益的患者的方法 IV级别在他们的身体。

9. 发明授权

US6040447A Purine compounds having PDE IV inhibitory activity and methods of synthesis 有权
标题翻译：具有PDE IV抑制活性的嘌呤化合物和合成方法
公开(公告)号：US6040447A
公开(公告)日：2000-03-21
申请号：US209922
申请日：1998-12-10
申请人： David J. Cavalla , Mark Chasin , Peter Hofer
发明人： David J. Cavalla , Mark Chasin , Peter Hofer
IPC分类号： A61K31/52 , A61K31/53 , A61P11/00 , A61P11/06 , A61P25/24 , A61P25/28 , A61P27/16 , A61P29/00 , A61P29/02 , A61P31/18 , A61P37/04 , A61P37/08 , A61P43/00 , C07D471/04 , C07D473/30 , C07D473/34 , C07D487/04 , C07D239/42 , C07D239/48
CPC分类号： C07D473/30 , C07D473/34
摘要： The present invention comprises a method of synthesizing compounds having the formula (I): ##STR1## wherein: Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.8 are defined herein, which comprises the steps of(a) reacting a compound of the formula (II) ##STR2## wherein Q is a halogen, with an effective amount of a compound selected from the group consisting of an acid anhydride or an acid halide; to form a compound of the formula (III) ##STR3## b) transforming the 6-halo group of said compound (III) to an amine by displacement with ammonia to form compound (IV) ##STR4## (c) reacting said compound (IV) with a base to cause cyclization to a 6-halo intermediate, said 6-halo group is then transformed to an amine by displacement with an amine to form compound (V) ##STR5## (d) reacting said compound (V) with an effective amount of compound (VI) ##STR6## wherein X is a halogen; to form the compound of formula (I).
摘要翻译：本发明包括合成具有式（I）的化合物的方法：其中：Z，R1，R2，R3，R4和R8如本文所定义，其包括以下步骤：（a）使式（II）其中Q是卤素，有效量的选自酸酐或酰卤的化合物; （III）的化合物b）通过用氨置换而将所述化合物（III）的6-卤代基转化成胺，以形成化合物（IV）（c）使所述化合物（IV）与碱反应导致环化成6-卤代中间体，然后用胺置换将6-卤代基转化成胺，形成化合物（Ⅴ）（d）使所述化合物（Ⅴ）与有效量的化合物（Ⅵ）反应，其中 X是卤素; 以形成式（I）的化合物。

10. 发明授权

US06211367B1 Methods of Synthesing Purine Compounds Having PDE Iv Inhibitory Activity 有权
标题翻译：合成具有PDE Iv抑制活性的嘌呤化合物的方法
公开(公告)号：US06211367B1
公开(公告)日：2001-04-03
申请号：US09210557
申请日：1998-12-11
申请人： David J. Cavalla , Mark Chasin , Peter Hofer
发明人： David J. Cavalla , Mark Chasin , Peter Hofer
IPC分类号： C07D47334
CPC分类号： C07D473/30 , C07D473/34
摘要： The present invention comprises compounds having the general formula I: wherein: Y, is N or CH Z is selected from the group consisting of alkyl groups such as alkylene groups such as CH2, CH2CH2, CH(CH3); alkenyl groups such as CH═CH; alkynyl groups such as C≡C; and NH, N(C1-C3 alkyl), O, S, C(O)CH2 and OCH2; R1 and R2 are selected from the group consisting of hydrogen and a C1-C8 straight or branched alkyl or a C3-C8 cycloalkyl; R3 is a C3-C12 straight or branched alkyl; R4 is a C3-C10 cycloalkyl optionally substituted with OH or C3-C10 cycloalkenyl optionally substituted with OH; and R8 is a C1-C8 straight or branched alkyl or a C3-C8 cycloalkyl, optionally substituted with OH; and methods of synthesis.
摘要翻译：本发明包括具有通式I的化合物：其中：Y是N或CHZ选自烷基如亚烷基如CH 2，CH 2 CH 2，CH（CH 3）; 烯基如CH = CH; 炔基如C = C; 和NH，N（C 1 -C 3烷基），O，S，C（O）CH 2和OCH 2; R 1和R 2选自氢和C 1 -C 8直链或支链烷基或C 3 -C 8环烷基; R3是C3-C12直链或支链烷基; R4是任选被OH或任选被OH取代的C 3 -C 10环烯基取代的C 3 -C 10环烷基; 和R 8是任选被OH取代的C1-C8直链或支链烷基或C3-C8环烷基;以及合成方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式